Meeting Banner
Abstract #2647

The study of vascular disrupting agent A64 combined with bevacizumab in the treatment of NSCLC using Multiple b-value DWI

Chang-Zheng Shi1, Dong Zhang2, Liang-Ping LUO3, and Yong Zhang4

1Jinan University, Guangzhou, China, People's Republic of, 2guangzhou, China, People's Republic of, 3Guangzhou, China, People's Republic of, 4GE Healthcare MR Research China, Beijing, Beijing, China, People's Republic of

Studies showed that vascular disrupting agents and angiogenesis inhibitors had a synergistic effect for the treatment of cancer. Few previous reports used MRI to assess the combination of anti-angiogenesis drugs in non-small cell lung cancer(NSCLC). MR multi-b value diffusion-weighted imaging can be used to monitor the treatment of tumor by anti-angiogenesis drugs. In our study , the nude mice xenograft model was used to evaluate the role of vascular disrupting agents combing angiogenesis inhibitor in NSCLC by multiple b-value diffusion weighted imaging (DWI).

This abstract and the presentation materials are available to members only; a login is required.

Join Here